Chitosan Composition for Arterial Plaque Density and IMT Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments and products are inadequate in effectively preventing or reducing the consequences of cardiovascular diseases, particularly in reducing arterial intima-media thickness and plaque density in blood vessels.
Innovation Solution
The use of chitosan with a number average molecular weight ranging from 80 kDa to 350 kDa, optionally combined with organic acids like ascorbic or tartaric acid, to reduce arterial intima-media thickness and control plaque density in blood vessels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chitosan or other existing treatments are used, then general cardiovascular disease prevention is attempted, but they are inadequate in effectively reducing arterial intima-media thickness and plaque density
Solution Approach 1:
The patent applies parameter changes by specifying a precise molecular weight range (80-350 kDa) for chitosan to optimize its therapeutic effectiveness. This parameter optimization enables the chitosan to effectively reduce arterial intima-media thickness and plaque density, resolving the contradiction between general prevention and specific therapeutic effectiveness.
2Manufacturing precision
If chitosan with unspecified molecular weight is used, then general cardiovascular benefits may be achieved, but the specific therapeutic effect on arterial intima-media thickness is insufficient
Solution Approach 1:
The patent specifies a precise molecular weight range (80-350 kDa) for chitosan to optimize its therapeutic effectiveness. This parameter optimization enables the chitosan to effectively reduce arterial intima-media thickness and plaque density, resolving the contradiction between general prevention and specific therapeutic effectiveness.
Data Source
Figure 1
AI summary
The present invention relates to a chitosan having number average molecular weight in the range from 50 kDa to 350 kDa and a medical product comprising said chitosan, for use as a product in a method of preventing or treating a cardiovascular disease.